Beckers A. Does preoperative somatostatin analog treatment improve surgical cure rates in acromegaly? A new look at an old question. J Clin Endocrinol Metab 2008;93(8):2975–7. https://www.ncbi.nlm.nih.gov/pubmed/18685119
Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365(9471):1644–6. https://www.ncbi.nlm.nih.gov/pubmed/15885297
Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract 2015;21(3):264–74. https://www.ncbi.nlm.nih.gov/pubmed/25370326
Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 2008;68(6):970–5. https://www.ncbi.nlm.nih.gov/pubmed/18031313
Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly: 2011 update. Endocr Pract . 2011;17(Suppl 4):https://www.ncbi.nlm.nih.gov/pubmed/21846616
Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, Pena L, Lugo G, Sangiao-Alvarellos S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One 2013;8(4):e61523. https://www.ncbi.nlm.nih.gov/pubmed/23634209
